Aspen Australia has launched Eikance 0.025% and Eikance 0.05% eye drops in addition to the existing Eikance 0.01% Eye Drops.
These additional strengths provide eye care professionals with greater treatment flexibility in managing progressive myopia when initiated in children aged 4-14 years. Atropine treatment may be initiated in children when myopia progresses ≥ 0.5 diopter or axial length increase of 0.2 mm per year.1
Eikance eye drops have been developed to support evidence-based myopia control strategies.1 This product range offers preservative-free, quality controlled, uniform and sterile pharmaceutical formulations that are available in convenient single-use ampoules.1
Myopia prevalence in children and young adults continues to rise globally, with increasing recognition of its long-term impact on ocular health.2,3,4 Early intervention and ongoing management play an important role in reducing the risk of associated complications later in life.4
Eikance eye drops have been developed to support evidence-based myopia control strategies
The introduction of Eikance 0.025% and Eikance 0.05% provides Australian eye care professionals with additional treatment options to support personalised care in clinical practice.
Eikance 0.01%, 0.025% and 0.05% are available through community pharmacies across Australia.
Before prescribing, please review Product Information available here or calling (AUS) 1300 659 646.
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at tga.gov.au/reporting-problems.
PBS Information |
|---|
| Eikance 0.01%, 0.025% and 0.05% are not listed on the PBS |
References:
- Eikance Product Information
- Australian Institute of Health and Welfare 2021. Eye health. Cat. no. PHE 260. Canberra: AIHW. Available at: aihw.gov.au/reports/eye-health/eye-health. Accessed March 2026.
- Holden BA et al. Ophthalmology 2016;123:1036–42.
- RANZCO. Position statement: Progressive myopia in childhood. June 2025.
